Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
There are no specific requirements and recommendations in the Russian Federation for evaluation of bioequivalence of modified-release medicinal products. Until recently, modified-release products were regulated in a similar manner as immediate-release products, which is unacceptable considering the...
Main Authors: | D. P. Romodanovsky, N. N. Eremenko, D. V. Goryachev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
NEICON ISP LLC
2019-03-01
|
Series: | Ведомости Научного центра экспертизы средств медицинского применения |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/218 |
Similar Items
-
Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic
by: D. P. Romodanovsky, et al.
Published: (2021-03-01) -
Highly variable medicines - specific aspects of bioequivalence studies
by: D. P. Romodanovsky, et al.
Published: (2018-02-01) -
PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS
by: N. E. Uvarova, et al.
Published: (2018-12-01) -
Expert Approaches to the Assessment of Losartan Drugs Bioequivalence
by: D. P. Romodanovsky, et al.
Published: (2020-02-01) -
Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State—A Case Study
by: Víctor Mangas-Sanjuán, et al.
Published: (2023-01-01)